Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

Spero Therapeutics reports Q1 2026 loss narrows; FDA to decide on oral antibiotic tebipenem HBr in June

Company Fundamentals
13 May 2026
GlobeNewsWire
View Source
Bullish
pluang ai news

Spero Therapeutics announced its financial results for Q1 2026, reporting a net loss of $7.2 million, an improvement from $13.9 million loss in Q1 2025, driven by reduced R&D and administrative expenses. The company is awaiting an FDA decision on its oral antibiotic tebipenem HBr for complicated urinary tract infections, with a PDUFA date set for June 18, 2026. Tebipenem HBr, developed with GSK, showed promising Phase 3 trial results, potentially offering a new oral treatment alternative to IV antibiotics. Spero maintains its cash runway guidance into 2028 and is exploring opportunities to expand its clinical-stage portfolio.

More News (GSK)

banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App